Angel Ferrandez

Prof. Angel Ferrandez

Hospital Clinico Lozano Blesa
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MDMaria Jose Domper-Arnal
Maria Jose Domper-Arnal
AFAngel Ferrandez
Angel Ferrandez
ÁAÁngel Lanas Arbeloa
Ángel Lanas Arbeloa
Esophageal cancer is one of the most unknown and deadliest cancers worldwide, mainly because of its extremely aggressive nature and poor survival rate. Esophageal cancer is the 6th leading cause of death from cancer and the 8th most common cancer in the world. The 5-year survival is around 15%-25%. There are clear differences between the risk factors of both histological types that affect their incidence and distribution worldwide. There are areas of high incidence of squamous cell carcinoma (some areas in China) that meet the requirements for cost-effectiveness of endoscopy for early diagnosis in the general population of those areas. In Europe and United States the predominant histologic subtype is adenocarcinoma. The role of early diagnosis of adenocarcinoma in Barrett’s esophagus remains controversial. The differences in the therapeutic management of early esophageal carcinoma (high-grade dysplasia, T1a, T1b, N0) between different parts of the world may be explained by the number of cancers diagnosed at an early stage. In areas where the incidence is high (China and Japan among others) early diagnoses is more frequent and has led to the development of endoscopic techniques for definitive treatment that achieve very effective results with a minimum number of complications and preserving the functionality of the esophagus.

1 January 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MNMercedes Navarro
Mercedes Navarro
ANAndrea Nicolas
Andrea Nicolas
AFAngel Ferrandez
Angel Ferrandez
ALAngel Lanas
Angel Lanas
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world. The incidence and mortality show wide geographical variations. Screening is recommended to reduce both incidence and mortality. However, there are significant differences among studies in implementation strategies and detection. This review aimed to present the results and strategies of different screening programs worldwide. We reviewed the literature on national and international screening programs published in PubMed, on web pages, and in clinical guidelines. CRC Screening programs are currently underway in most European countries, Canada, specific regions in North and South America, Asia, and Oceania. The most extensive screening strategies were based on fecal occult blood testing, and more recently, the fecal immunochemical test (FIT). Participation in screening has varied greatly among different programs. The Netherlands showed the highest participation rate (68.2%) and some areas of Canada showed the lowest (16%). Participation rates were highest among women and in programs that used the FIT test. Men exhibited the greatest number of positive results. The FIT test has been the most widely used screening program worldwide. The advent of this test has increased participation rates and the detection of positive results.

28 April 2016 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
GOGonzález
González
CACarlos A.
Carlos A.
SASanz‐ Anquela
Sanz‐ Anquela
JMJosé Miguel
José Miguel
OCOsmel Companioni
Osmel Companioni
JGJavier P. Gisbert
Javier P. Gisbert

1 January 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
IPIgnasi Puig
Ignasi Puig
MLMaría López-Cerón
María López-Cerón
AAAnna Arnau
Anna Arnau
ÒRÒria Rosiñol
Òria Rosiñol
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
NANadia Ascon
Nadia Ascon

1 June 2017 in Trends in Cancer
Verified
Journal Article
Closed access
MAMaykel Arias
Maykel Arias
LMLuis Martínez-Lostao
Luis Martínez-Lostao
LSLlipsy Santiago
Llipsy Santiago
AFAngel Ferrandez
Angel Ferrandez
DGDavid J. Granville
David J. Granville
JPJulian Pardo
Julian Pardo

1 October 2004 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
AFAngel Ferrandez
Angel Ferrandez
WSWade Samowitz
Wade Samowitz
JDJames A. DiSario
James A. DiSario
RBRandall W. Burt
Randall W. Burt
Hyperplastic polyposis (HP) is a poorly understood condition. The aim of this study is to describe the phenotype and the risk of cancer in HP. Patients with HP, as defined by the WHO International Classification, were identified through the University of Utah and the Huntsman Cancer Institute databases. Family history was retrieved when possible. Fifteen patients were identified (10 M, 5 F) with a mean age at diagnosis of 52.6 ± 16.4 yr (18–71). Sixty-five colonoscopies were performed (2–11 per person). A median of 90 polyps (16–210) per person and 15 polyps (range, 0–100) per procedure were reported. The median follow-up was 33 months (3–133); no cancer occurred during this period. Polyps were more frequent in the distal than the proximal colon (74% vs 26%; p < 0.001). The median polyp size was 4 mm (1–40 mm). Fifty-one hyperplastic polyps >10 mm were identified in 10 patients (38 proximal, 13 distal; P = 0.089). Forty-eight adenomas were found in 11 patients and were uniformly distributed. Serrated adenomas (n = 3) were found in one patient. A unique patient had 20 large hyperplastic polyps, 24 adenomas, 3 serrated adenomas, and 118 hyperplastic polyps. None of the patients had a first-degree relative with colon cancer. In HP, hyperplastic polyps are more frequently distal colonic, and vary greatly in size and number. Most patients also develop adenomas that are distributed throughout the colon. No cancers developed within 3 yr of follow-up. Colonoscopic surveillance at intervals of 1–3 yr, depending upon the number and size of both adenomatous and hyperplastic polyps, appears prudent.